Cargando…
NSC Physiological Features in Spinal Muscular Atrophy: SMN Deficiency Effects on Neurogenesis
While the U.S. Food and Drug Administration and the European Medicines Evaluation Agency have recently approved new drugs to treat spinal muscular atrophy 1 (SMA1) in young patients, they are mostly ineffective in older patients since many motor neurons have already been lost. Therefore, understandi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736802/ https://www.ncbi.nlm.nih.gov/pubmed/36499528 http://dx.doi.org/10.3390/ijms232315209 |